ArticlePulmonary circulation2025
Prevalence and Economic Burden of Pulmonary Hypertension and Pulmonary Arterial Hypertension Among the Medicaid Population.
Article in Pulmonary circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pulmonary hypertension (PH) is defined hemodynamically as a mean pulmonary arterial pressure (mPAP) ≥ 20 mmHg, measured at right heart catheterization (RHC). Pulmonary arterial hypertension (PAH) is defined as a mPAP ≥ 20 mmHg with a pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) of ≤ 15 mmHg and a pulmonary vascular resistance (PVR) > 2 Woods Units (WU). The reported prevalence of PAH in the general population is 0.03-0.05 per 1000 population. However, several studies suggest that the prevalence may be higher among specific sub-populations. Using Medicaid Analytic Extract (MAX) files, we identified Medicaid beneficiaries who were diagnosed with PH or PAH between 2009 and 2012. The prevalence of PH and PAH was calculated for the overall study population and subgroups based on demographics or co-morbidities. We used one-way analysis of variance (ANOVA) tests to compare the differences in hospital bed days and total Medicaid cost across racial subgroups among those with PH and those without PH; Tukey post hoc tests were performed to calculate p-values for comparing White and Black subpopulations. Prevalence rates ranged between 1.7 and 1.8 per 1000 persons, and the PAH prevalence ranged between 0.4 and 0.5 per 1000 persons for the years reviewed. Significant racial/ethnic disparity in PH and PAH prevalence was observed (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.